Antiarrhythmic agents for chronic ventricular arrhythmias.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Numerous antiarrhythmic agents are available for clinical use.
• The efficacy of antiarrhythmic agents in preventing sudden cardiac death remains unestablished.
• Risk-benefit assessment is crucial due to potential drug-related risks.

Purpose of the Study:

• To review current strategies for managing ventricular arrhythmias.
• To discuss the selection of antiarrhythmic agents based on arrhythmia type and patient condition.
• To highlight considerations for drug selection in specific patient populations.

Main Methods:

• Review of existing literature on antiarrhythmic drug therapy.
• Analysis of clinical guidelines and expert recommendations.
• Discussion of drug properties, including potency, side effects, and proarrhythmic potential.

Main Results:

• For benign or potentially lethal symptomatic ventricular arrhythmias, beta blockers or potent class IC agents (flecainide, encainide) are often initial choices due to low side effects and high potency.
• For lethal ventricular arrhythmias without heart failure, drugs with minimal negative inotropic effects (quinidine, encainide) or combinations of class IA and IB agents are recommended.
• In patients with severe heart failure and lethal arrhythmias, amiodarone is reserved for cases refractory to other agents; disopyramide, beta blockers, and flecainide should be avoided.

Conclusions:

• Antiarrhythmic drug selection requires careful consideration of arrhythmia severity, patient symptoms, and underlying cardiac function.
• Potent class IC agents offer effective treatment for many ventricular arrhythmias with a favorable side effect profile.
• Specific patient groups, particularly those with heart failure, necessitate cautious drug selection to minimize risks.